Risk reduction strategies for ductal carcinoma in situ

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue 10, 2010, Pages 1211-1217

  Cohen, Adam L ^a   Ward, John H ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Ductal carcinoma in situ; Radiotherapy; Risk reduction behavior; Secondary prevention; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CARBOPLATIN; CHLOROQUINE; DENDRITIC CELL VACCINE; DOXORUBICIN; ESTROGEN RECEPTOR; EXEMESTANE; FENRETINIDE; FLUINDOSTATIN; FULVESTRANT; GEFITINIB; LAPATINIB; OMEGA 3 FATTY ACID; PLACEBO; PROGESTERONE RECEPTOR; RALOXIFENE; TAMOXIFEN; TRASTUZUMAB; VORINOSTAT;

ADJUVANT THERAPY; BREAST CANCER; BROCCOLI; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; DRUG SAFETY; ENDOMETRIUM CANCER; HUMAN; INTRADUCTAL CARCINOMA; LIFESTYLE MODIFICATION; LINSEED; LOW FAT DIET; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PHYSICAL ACTIVITY; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; RISK MANAGEMENT; RISK REDUCTION; STROKE; TEA; THROMBOEMBOLISM; WEIGHT REDUCTION;

EID: 78951475903     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0088     Document Type: Review

References (44)

1. Pinder SE, Ellis IO. The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH) - current definitions and classification. Breast Cancer Res 2003;5:254-257.
2. Allegra CJ, Aberle DR, Ganschow P, et al. National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009. J Natl Cancer Inst 2010;102:161-169.
3. Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 2005;103:2481-2484.
4. Collins LC, Tamimi RM, Baer HJ,et al. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer 2005;103:1778-1784.
5. Eusebi V, Feudale E, Foschini MP, et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol 1994;11:223-235.
6. Betsill WL Jr, Rosen PP, Lieberman PH, Robbins GF. Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone. JAMA 1978;239:1863-1867.
7. Hughes LL, Wang M, Page DL, et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27:5319-5324.
8. Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol 2000;18:3172-3186.
9. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:1993-2000. (Pubitemid 29271743)
10. Allred D, Bryant J, Land S, et al. Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: findings from NSABP protocol B-24 [abstract]. Breast Cancer Res Treat 2002;76(Suppl 1):S36. Abstract 30.
11. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-5312.
12. Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 2003;362:95-102.
13. Decensi A, Robertson C, Guerrieri-Gonzaga A, et al. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J Clin Oncol 2009;27:3749-3756.
14. Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 2003;18:937-947.
15. Boehm DU, Lebrecht A, Eckhardt T, et al. Quality of life and adjuvant tamoxifen treatment in breast cancer patients. Eur J Cancer Care (Engl) 2009;18:500-506.
16. Schilder CM, Seynaeve C, Beex LV, et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 2010;28:1294-1300.
17. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 2010;28:4120-4128.
18. Vogel VG, Costantino JP, Wickerham L, et al. Update of the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer. Presented at the American Association for Cancer Research (AACR) 101st Annual Meeting; April 17-21, 2010; Washington, DC.
19. Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998;16:441-452.
20. Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 - a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006;24:3381-3387.
21. Emdin SO, Granstrand B, Ringberg A, et al. SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol 2006;45:536-543.
22. Ballard-Barbash R, Hunsberger S, Alciati MH, et al. Physical activity, weight control, and breast cancer risk and survival: clinical trial rationale and design considerations. J Natl Cancer Inst 2009;101:630-643.
23. Viani GA, Stefano EJ, Afonso SL, et al. Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials. Radiat Oncol 2007;2:28.
24. Burstein HJ, Polyak K, Wong JS, et al. Ductal carcinoma in situ of the breast. N Engl J Med 2004;350:1430-1441.
25. Silverstein MJ. The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 2003;186:337-343.
26. Gilleard O, Goodman A, Cooper M, et al. The significance of the Van Nuys prognostic index in the management of ductal carcinoma in situ. World J Surg Oncol 2008;6:61.
27. Di Saverio S, Catena F, Santini D, et al. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up. Breast Cancer Res Treat 2008;109:405-416.
28. MacAusland SG, Hepel JT, Chong FK, et al. An attempt to independently verify the utility of the Van Nuys Prognostic Index for ductal carcinoma in situ. Cancer 2007;110:2648-2653.
29. Boland GP, Chan KC, Knox WF, et al. Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery. Br J Surg 2003;90:426-432.
30. Cornfield DB, Palazzo JP, Schwartz GF, et al. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cancer 2004;100:2317-2327.
31. Ahn J, Schatzkin A, Lacey JV Jr, et al. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med 2007;167:2091-2102.
32. Eliassen AH, Colditz GA, Rosner B, et al. Adult weight change and risk of postmenopausal breast cancer. JAMA 2006;296:193-201. (Pubitemid 44050373)
33. Feigelson HS, Patel AV, Teras LR, et al. Adult weight gain and histopathologic characteristics of breast cancer among postmenopausal women. Cancer 2006;107:12-21.
34. Huang Z, Hankinson SE, Colditz GA, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA 1997;278:1407-1411.
35. Kumar NB, Lyman GH, Allen K, et al. Timing of weight gain and breast cancer risk. Cancer 1995;76:243-249.
36. Pierce JP, Natarajan L, Caan BJ, et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA 2007;298:289-298.
37. Gold EB, Pierce JP, Natarajan L, et al. Dietary pattern influences breast cancer prognosis in women without hot flashes: the women's healthy eating and living trial. J Clin Oncol 2009;27:352-359.
38. Chlebowski RT, Blackburn GL, Thomson CA, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst 2006;98:1767-1776.
39. Chlebowski RT Blackburn GL, Hoy MK, et al. Women's Intervention Nutrition Study Survival analyses from the Women's Intervention Nutrition Study (WINS) evaluating dietary fat reduction and breast cancer outcome. J Clin Oncol 2008;26(Suppl 1):Abstract 522.
40. Prentice RL, Caan B, Chlebowski RT, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006;295:629-642. (Pubitemid 43209065)
41. Cerhan JR, Chiu BC, Wallace RB, et al. Physical activity, physical function, and the risk of breast cancer in a prospective study among elderly women. J Gerontol A Biol Sci Med Sci 1998;53:M251-256.
42. Bardia A, Hartmann LC, Vachon CM, et al. Recreational physical activity and risk of postmenopausal breast cancer based on hormone receptor status. Arch Intern Med 2006;166:2478-2483.
43. McTiernan A, Kooperberg C, White E, et al. Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort study. JAMA 2003;290:1331-1336.
44. Patel AV, Press MF, Meeske K, et al. Lifetime recreational exercise activity and risk of breast carcinoma in situ. Cancer 2003;98:2161-2169.